December 16, 2021
A-Alpha Bio Partners with Kymera Therapeutics to Discover Novel Interactions for Molecular Glue Discovery
Today A-Alpha Bio announced that we’ve partnered with Kymera Therapeutics to discover and characterize novel pairs of E3 ubiquitin ligases and high-value therapeutic targets for the rational and prospective design and development of molecular glues.
This is the first partnership we’ve announced in the cutting-edge and rapidly growing area of targeted protein degradation, and we’re particularly excited to collaborate with the wonderful team at Kymera to discover and validate molecular glue targets!
Coverage in SynBioBeta can be read here.